Organisation paid for research Program year 2025 Source: CMS Open Payments

Ironwood Physicians, PC

Neither a doctor nor a teaching hospital

Research payments

$446,579

65 payments

Through program year 2025, Ironwood Physicians, PC is reported as receiving $446,579 in research payments, across 65 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$126,066	13
2024	Research	$17,076	6
2023	Research	$16,818	3
2022	Research	$110,821	13
2021	Research	$35,393	3
2020	Research	$100,816	21
2019	Research	$39,590	6

Breakdown

Who paid Research payments · program years 2019–2025

Daiichi Sankyo Inc. $400,989 56 payments
AbbVie, Inc. $34,126 4 payments
Karyopharm Therapeutics Inc. $6,000 3 payments
Celgene Corporation $5,121 1 payment
Incyte Corporation $343 1 payment

Studies the money was for Research payments · program years 2019–2025

Ds1062-A-U301 $141,057 18 payments
Ds1062-A-U303 $92,987 9 payments
Ds1062-A-U304 $66,130 8 payments
Study name not reported $64,217 11 payments
Study name not reported $36,598 10 payments
M14-064 $34,126 4 payments
A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) $6,000 3 payments
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Lymphoma (RV-FOL-GELARC-0683C) $5,121 1 payment
A Randomized, Double Blind, Phase 3 Study of the JAK1 2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First Line Chemotherapy The JANUS 1 Study $343 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.